Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Total Valuation
Fulcrum Therapeutics has a market cap or net worth of $498.72M. The enterprise value is $223.76M.
Market Cap$498.72M
Enterprise Value$223.76M
Share Statistics
Fulcrum Therapeutics has 54,091,587 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,091,587
Owned by Insiders7.54%
Owned by Institutions<0.01%
Financial Efficiency
Fulcrum Therapeutics’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -8.62%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-8.62%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee1.78M
Profits Per Employee-216.11K
Employee Count45
Asset Turnover0.31
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fulcrum Therapeutics is ―. Fulcrum Therapeutics’s PEG ratio is 0.33.
PE Ratio―
PS Ratio3.64
PB Ratio1.20
Price to Fair Value1.20
Price to FCF-116.72
Price to Operating Cash Flow-9.76
PEG Ratio0.33
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 80.00M and earned -9.72M in profits. Earnings per share was -0.17.
Revenue80.00M
Gross Profit78.41M
Operating Income-21.90M
Pretax Income-9.72M
Net Income-9.72M
EBITDA-18.24M
Earnings Per Share (EPS)-0.17
Cash Flow
In the last 12 months, operating cash flow was -60.03M and capital expenditures -386.00K, giving a free cash flow of -60.41M billion.
Operating Cash Flow-60.03M
Free Cash Flow-60.41M
Free Cash Flow per Share-1.12
Dividends & Yields
Fulcrum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.49
52-Week Price Change196.20%
50-Day Moving Average8.12
200-Day Moving Average5.89
Relative Strength Index (RSI)54.37
Average Volume (3m)501.71K
Important Dates
Fulcrum Therapeutics upcoming earnings date is Feb 26, 2026, Before Open (Confirmed).
Last Earnings DateOct 29, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Fulcrum Therapeutics as a current ratio of 22.63, with Debt / Equity ratio of 3.53%
Current Ratio22.63
Quick Ratio22.63
Debt to Market Cap<0.01
Net Debt to EBITDA2.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fulcrum Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fulcrum Therapeutics EV to EBITDA ratio is -13.25, with an EV/FCF ratio of -96.85.
EV to Sales3.02
EV to EBITDA-13.25
EV to Free Cash Flow-96.85
EV to Operating Cash Flow-108.99
Balance Sheet
Fulcrum Therapeutics has $200.65M in cash and marketable securities with $7.01M in debt, giving a net cash position of $193.63M billion.
Cash & Marketable Securities$200.65M
Total Debt$7.01M
Net Cash$193.63M
Net Cash Per Share$3.58
Tangible Book Value Per Share$3.92
Margins
Gross margin is 0.00%, with operating margin of -27.37%, and net profit margin of -12.16%.
Gross Margin0.00%
Operating Margin-27.37%
Pretax Margin-12.16%
Net Profit Margin-12.16%
EBITDA Margin-22.80%
EBIT Margin-24.79%
Analyst Forecast
The average price target for Fulcrum Therapeutics is $13.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.00
Price Target Upside38.89% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast-100.00%
EPS Growth Forecast-266.37%